Skip to main content
. 2016 Mar 9;7(15):20704–20717. doi: 10.18632/oncotarget.8007

Figure 4. Association of EPB41L4A-AS2 expression with lung cancer patient survival in cohort III.

Figure 4

(A) EPB41L4A-AS2 expression and OS of lung cancer patients (N = 1926). (B) EPB41L4A-AS2 expression and post-progression survival of lung cancer patients (N = 344). (C) EPB41L4A-AS2 expression and OS of lung cancer patients with chemotherapy (N = 176), and without chemotherapy (N = 310) (D).